LRMR - Larimar Therapeutics, Inc.
NEXT EARNINGS:
Mar 23, 2026
(in 26 days)
EPS Est: $-0.41
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.00
DETAILS
HIGH:
$7.00
LOW:
$7.00
MEDIAN:
$7.00
CONSENSUS:
$7.00
UPSIDE:
89.70%
Market Cap:
315.83M
Volume:
70,217,492
Avg Volume:
1,245,136
52 Week Range:
1.61-5.37
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.00
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
65
IPO Date:
2014-06-19
EPS (TTM):
-1.32
P/E Ratio:
-2.94
Revenue (TTM):
N/A
Total Assets:
200.22M
Total Debt:
5.12M
Cash & Equiv:
33.22M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-51.7%
Debt/Equity:
0.03
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.61 | $-0.39 | -56.4% | — | — | — |
| 2025-08-14 | $-0.41 | $-0.47 | +12.8% | — | — | — |
| 2025-04-30 | $-0.46 | $-0.42 | -9.5% | — | — | — |
| 2025-03-24 | $-0.45 | $-0.29 | -55.2% | $241000 | — | — |
| 2024-10-30 | $-0.24 | $-0.37 | +35.1% | — | — | — |
| 2024-08-07 | $-0.34 | $-0.32 | -6.3% | — | — | — |
| 2024-05-09 | $-0.27 | $-0.24 | -12.5% | — | — | — |
| 2024-03-14 | $-0.30 | $-0.25 | -20.0% | — | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (80.60M) | (36.95M) | (35.35M) | (50.64M) | (42.33M) | (23.13M) | (61.37M) | (52.03M) | (57.88M) | (74.29M) | (36.57M) | (14.03M) |
| EPS | -1.32 | -0.84 | -1.33 | -2.93 | -3.56 | -2.51 | -22.85 | -22.76 | -25.44 | -33.32 | -15.14 | -6.54 |
| Total Assets | 200.22M | 95.94M | 126.41M | 78.67M | 104.69M | 5.20M | 121.76M | 105.51M | 131.62M | 189.11M | 117.52M | 38.14M |
| Total Debt | 5.12M | 5.55M | 5.41M | 6.00M | 6.52M | 97,000 | 20.64M | 20.00M | 3.59M | 6.39M | 7.56M | 0 |
| Cash & Equivalents | 33.22M | 26.75M | 26.82M | 70.10M | 68.15M | 1.01M | 49.33M | 40.78M | 32.35M | 35.59M | 58.10M | 35.52M |
| Operating Cash Flow | (70.76M) | (33.46M) | (27.57M) | (42.10M) | (42.20M) | (22.70M) | (51.49M) | (43.78M) | (51.98M) | (59.55M) | (28.24M) | (15.00M) |
| Free Cash Flow | (71.28M) | (33.62M) | (27.67M) | (42.44M) | (42.26M) | (22.78M) | (51.59M) | (43.84M) | (52.63M) | (60.15M) | (28.30M) | (15.02M) |
| FCF per Share | -1.16 | -0.77 | -1.07 | -2.47 | -3.56 | -2.47 | -19.21 | -19.18 | -23.14 | -26.98 | -11.71 | -6.90 |
| Book Value | 171.81M | 81.72M | 110.90M | 64.41M | 89.69M | (694,000) | 93.27M | 78.22M | 121.73M | 169.11M | 104.44M | 35.22M |
| Cash & ST Investments | 183.45M | 86.79M | 118.43M | 70.10M | 92.64M | 1.01M | 118.07M | 102.05M | 129.19M | 185.08M | 115.46M | 35.52M |
| ROC Equity | -0.47 | -0.45 | -0.32 | -0.79 | -0.47 | N/A | -0.66 | -0.67 | -0.48 | -0.44 | -0.35 | -0.40 |